American Association of Internal Artificial Organs 2022 Annual Conference


American Society for Artificial Internal Organs 2022

Chicago, IL – June 8, 2022 – SynCardia Systems, LLC, exhibits at the American Society of Artificial Internal Organs annual conference.

There is no better place than the Annual Conference of the American Society for Artificial Internal Organs to learn more about artificial internal organs and the development of them. This conference has been existing over 64 years and brings scientists, engineers, and medical professionals together from around the world to discuss the development of innovative medical device technology at the intersection of science, engineering, and medicine.

At this conference, there were be a scientific exhibit which is designed to provide an opportunity to display products and services that are either specifically designed for, or customarily used when purchasing or delivering products used in artificial internal organ procedures.

It was an honor for us to be able to attend this year’s conference in Chicago, Illinois on 2022 to learn more about our medical department as well as to contribute to the development of the technology we will be utilizing in the future. It has been a great experience to attend ASAIO this year, and we are looking forward to attending the conference in San Francisco in 2023. 

About SynCardia Systems, LLC

Headquartered in Tucson, Ariz., SynCardia manufactures the world’s only commercially approved total artificial heart. In clinical use for more than 35 years and with more than 1,800 implants, the SynCardia temporary Total Artificial Heart (TAH) is the most widely used and extensively studied TAH in the world.

By partnering with, training and supporting healthcare teams at more than 140 transplant hospitals and heart failure programs in more than 20 countries, SynCardia helps create better outcomes for critically ill adults and adolescents whose best chance at survival is total heart replacement. When a donor heart isn’t an available option, SynCardia provides a new heart without the wait for patients with end-stage heart failure affecting both sides of the heart (biventricular failure).

Leave a Comment

Your email address will not be published. Required fields are marked *